CSR Conclave: 'Empowering Tribals through CSR' (See 'Corp Brief') CSIR & MEA jointly host Ambassadors from Global South (See 'Corp Brief') Nadda reaffirms India's Commitment to Eliminate TB Ahead of Global Targets (See 'Corp Brief') Ministry of Ayush and DBT announce collaborative Clinical Study on Ayurveda (See 'Corp Brief') IBC - Issues of fraud or existence of debt must be decided by insolvency tribunal, not civil court: HC (See 'Legal Desk') RBI strengthens Framework on Unauthorised Electronic Banking Transactions (See 'Corp Brief') Govt expands DEH Initiative to Boost District-Level Export Competitiveness (See 'Corp Brief') DPIIT signs MoU with leading AC company to strengthen manufacturing ecosystem (See 'Corp Brief') Two-Day Eastern Region Review Meeting of CGCA concludes (See 'Corp Brief') IPR - Minor variations in product that do not alter essential mode of operation of patented invention are considered mere engineering variations: HC (See 'Legal Desk') Paatil calls for 'Jan Bhagidari' to strengthen Water Conservation Efforts (See 'Corp Brief') IICA successfully concludes 4th Batch of Directors' Certification in Corporate Governance (See 'Corp Brief') Ministry of MSME assisting entrepreneurs in setting up of new micro enterprises (See 'Corp Brief') COFEPOSA - Dispute over rent or mesne profits for immovable property leased for commercial purposes is 'commercial dispute': HC (See 'Legal Desk') Amendments to Banking Regulation Act and MSCS Act, 2002 enhance oversight & accountability (See 'Corp Brief') MY Bharat mobilises Youth across 763 Districts for Shaheed Diwas Padyatra (See 'Corp Brief') PMLA - Even property acquired prior to commission of crime can be provisionally attached finding it falling in definition of 'proceeds of crime': SAFEMA (See 'Legal Desk') Ministry of Mines to launch 7th Tranche of Auction of Critical and Strategic Minerals (See 'Corp Brief') Jal Mahotsav 2026 gives momentum to 'Jal Sanchay se Jan Bhagidari' (See 'Corp Brief') Ministry of Mines to organise National DMF Summit 2026 (See 'Corp Brief') PMLA - High Court of Delhi lacked territorial jurisdiction to hear appeal filed against Appellant based in Kolkata; GST registration at Delhi, occasional hearings before Delhi Bench of NCLT do not establish that appellant ordinarily operates in Delhi: HC (See 'Legal Desk') Union Minister chairs 90th Meeting of Standing Committee of National Board for Wildlife (See 'Corp Brief') India achieves 1 billion Tonne Coal Production Milestone Again (See 'Corp Brief') Capital Market - SEBI's regulations are framed to protect rights of stakeholders in securities market, and violation of its regulations being matter of public law, can't be condoned by private resolution of shareholders: SC (See 'Legal Desk') PDUNASS conducts DoPT-Sponsored Training Programme (See 'Corp Brief') Govt introduces Credit Guarantee Scheme for Microfinance Institutions-2.0 (See 'Corp Brief') Supreme Court Clears Path For Single Insolvency Proceedings Against Linked Group Companies (See CORP EINSICHT)

Print

NPPA monitors prices of scheduled & non-scheduled medicines

Published: Jul 30, 2024

By TIOLCorplaws News Service

NEW DELHI, JULY 30, 2024: AS per the provisions of Drugs (Prices Control) Order, 2013 (DPCO, 2013), formulations listed in Schedule-I of the DPCO are defined as scheduled formulation under section 2(1)(zb) of DPCO, 2013. Formulations not included in Schedule-I are defined under Para 2(1)(v) of DPCO, 2013 as non-scheduled formulation. Thus, both schedule and non-schedule drugs are covered under DPCO, 2013. 

As per the extant provisions of DPCO, 2013, the ceiling prices of scheduled medicines are revised annually on the basis of Wholesale Price Index (WPI) (all commodities) for preceding calendar year by National Pharmaceutical Pricing Authority (NPPA), on or before 1st April of every year and is notified by the Government on the 1st day of April every year. The details of price fixed by NPPA are available at NPPA's website i.e. nppaindia.nic.in.  In case of non-scheduled formulation (branded or generic), as per para 20 of DPCO, 2013, no manufacturers can increase Maximum Retail Price (MRP) by more than 10% of MRP during preceding 12 months.  The maximum permissible increase in prices, as per the provisions of DPCO, 2013 for scheduled and non-scheduled drugs may or may not be availed by their respective manufacturers based on commercial considerations and market dynamics.

Under the Drugs and Cosmetics Act, 1945 and Rules thereunder, manufacturers of drugs are required to comply with conditions of manufacturing licence and the requirements of Good Manufacturing Practices (GMP).  As per the Drugs Rules, 1945, the manufacturing, testing, labeling, packaging, storage and distribution are required to be carried out in compliance with the conditions of license including the Good manufacturing practices (GMP) prescribed under the Schedule M of the Drugs Rules, 1945. In case of violation, the Licensing Authority is empowered to take action as per the said Act and Rules.

NPPA monitors the prices of scheduled as well as non-scheduled medicines under DPCO, 2013.  Action is taken against companies, found selling formulations at prices higher than the permissible price, and the overcharged amount is recovered from the company as per the relevant provisions of the DPCO, 2013. During the financial year 2023-24, Rs. 72.73 crore was recovered from the defaulting companies.

This information was given by the Union Minister of State for Chemicals and Fertilizers Anupriya Patel in Rajya Sabha in reply to a question today.

TIOL CORP SEARCH

TIOL GROUP WEBSITES

taxindiaonline
taxindiainternational
tioltube
TKF
TIOLawards
A TIOL Website. Copyright © 2025 TIOLcorplaws.com All rights reserved.